Plasma Test Increases Access to Alzheimer's Testing: Alicia Algeciras-Schimnich, Ph.D. - Insights
Plasma Test Increases Access to Alzheimer’s Testing: Alicia Algeciras-Schimnich, Ph.D. Answers From the Lab In this episode of “Answers From the Lab,”
Learn more about how Mayo Clinic Laboratories’ targeted, high-resolution screening panel for stimulant use identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test.
B-cell and T-cell acute lymphoblastic leukemia - Insights
Find out how our suite of B-cell and T-cell acute lymphoblastic leukemia tests can detect genetic subgroups and assist in treatment selection.
Genetic Testing to Enhance Multiple Myeloma Treatment - Insights
Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against...
MCL Molecular Genetics Inherited Cancer Syndromes Patient Information MC123598
MCL Molecular Genetics Inherited Cancer Syndromes Patient Information Complete print Reset Form Molecular Genetics Inherited Cancer Syndromes Patient Information Instructions accurate interpretation reporting genetic
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) - Insights
In this month's "Hot Topic," Eoin Flanagan, M.B., B.Ch., reviews the recent diagnostic criteria for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD).
Innovative Alzheimer's disease diagnostic tool unveiled - Insights
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative...
Patients with Blood Cancer Precursor at Risk of Developing Cancer Even after 30 Years - Insights
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer─even after 30 years of stability, according to findings of a study by Mayo Clinic researchers published in...
Frontotemporal dementia and ALS - Insights
Learn more about how detection of amyotrophic lateral sclerosis and frontotemporal dementia paved the way for gene-targeted therapies for patients.
Dementia with Lewy bodies, Parkinson's, and multiple system atrophy - Insights
Learn more about how Mayo Clinic Laboratories' cerebrospinal fluid biomarker test for synucleinopathies, such as Parkinson’s disease and dementia with Lewy bodies, can accurately identify α-syn pathology even before definitive symptoms...